Please provide your email address to receive an email when new articles are posted on . High FeNO levels indicate exacerbation and lung function risks. Most patients with high FeNO levels also had ...
Please provide your email address to receive an email when new articles are posted on . The treatment group had reductions in FeNO 1 week after a single dose. Reductions were significant compared with ...
In a recent study published in the Respiratory Research journal, researchers in Hong Kong assessed the deterioration of asthma control in patients recovering from mild to moderate coronavirus disease ...
Mild asthma could be better treated with the recent approval of the combination of albuterol/budesonide. The recent approval of albuterol/budesonide could change the way that mild asthma is treated in ...
Earlier this month, Apogee Therapeutics reported positive interim Phase 1b data for zumilokibart (APG777) in mild-to-moderate asthma, showing a favorable safety profile and durable suppression of Type ...
In the trial, zumilokibart demonstrated: The only treatment-emergent adverse event (TEAE) observed in more than one patient was gastroesophageal reflux disease (GERD; 2 patients). There were no Grade ...
As-needed use of a metered-dose inhaler with albuterol plus budesonide (Airsupra) lowered the risk of severe exacerbations compared with albuterol alone for people with normally mild asthma, the phase ...
Among patients with mild to moderate COVID-19, the asthma drug montelukast (Singulair) did not reduce duration of symptoms, results of the randomized controlled ACTIV-6 trial showed. After receiving ...
In many patients, annual short-acting beta2-agonist prescription fulfillment is indicative of uncontrolled disease and increased incidence of exacerbations. Credit: Getty Images. Short-acting beta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results